• Tuesday, June 7, 2022 @ 12:00 am

Encouraging evenamide "Study 014" interim data in treatment-resistant schizophrenia (TRS) confirm good safety and improvement of symptoms of psychosis in heavily pre-treated patients. Newron continues to trade well below the value of Xadago with no value contributed to its pipeline targeting blockbuster sales.

Key catalysts include:

  • Start new label trial Xadago in PD-LID (Q3 2022)
  • Results “Study 014” of evenamide in TRS (Q3 2022)
  • Results “Study 008A” of evenamide in non-TRS (Q4 2022)

Full Newron valuation report update "Back to pivotal"

You may also be interested in